Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials

INTRODUCTION: Nintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event profile that is manageable for most patients. We used data from six clinical trials to characterise the safety and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lancaster, Lisa, Crestani, Bruno, Hernandez, Paul, Inoue, Yoshikazu, Wachtlin, Daniel, Loaiza, Lazaro, Quaresma, Manuel, Stowasser, Susanne, Richeldi, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530503/
https://www.ncbi.nlm.nih.gov/pubmed/31179001
http://dx.doi.org/10.1136/bmjresp-2018-000397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530503/
https://www.ncbi.nlm.nih.gov/pubmed/31179001
http://dx.doi.org/10.1136/bmjresp-2018-000397

Ejemplares similares